Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DLB34X
|
|||
| Drug Name |
GS030
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Retinitis pigmentosa [ICD-11: 9B70; ICD-10: H35.5] | Phase 1/2 | [1] | |
| Company |
GenSight Biologics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03326336) A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.